To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 50 years * Choroidal neovascularization secondary to AMD * Best corrected visual acuity in the study eye between 20/25 to 20/400 using an ETDRS chart * Documentation of presence of subretinal fluid and/or cystoid macular edema on SD-OCT following at least four anti-VEGF treatments within six months before enrollment and a maximum of 5 years of years of treatment for neovascular AMD * Documentation of presence of subretinal fluid and/or cystoid macular edema less than 30 days since last treatment Exclusion Criteria: * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. * Participation in another simultaneous medical investigation or trial * Prior treatment with anti-VEGF therapy in the study eye within 30 days of BSL * Prior treatment with PDT within the past 3 months or more than 4 prior PDT treatments. * Presence of significant subfoveal fibrosis or atrophy. * Prior treatment with intravitreal aflibercept injection * Prior treatment with triamcinolone in the study eye within 6 months of BSL. * Prior treatment with dexamethasone in the study eye within 30 days prior to BSL * Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding BSL * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye * Active intraocular inflammation (grade trace or above) in the study eye * Current vitreous hemorrhage in the study eye * History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye * Ocular or periocular infection * Active severe intraocular inflammation * Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication) * History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment. * History of allergy to fluorescein, ICG or iodine, not amenable to treatment * Known hypersensitivity to aflibercept or to any of the excipients